

## For Health Professionals Who Care for Cancer Patients

### Inside This Issue:

#### Editor's Choice

**New Programs** Intravesical Aldesleukin for In-Transit Melanoma (SMILALD)

#### Policy Updates

Dose Banding | High-Alert Medications

#### Cancer Drug Manual®

**New** Sonidegib | **Revised** Arsenic Trioxide

#### Benefit Drug List

**New** SMILALD

#### New Protocols, PPPOs & Patient Handouts

**GI** UGIGAVTRFT | **GU** GUAVD, GUAXIT, GUCABO, GUEDPM, GUEP, GUMVAC, UGUNMPENZ, UGUPAPA, UGUPENZ, GUPLHRH, GUPLHRHA, GUPMX, GUPNSAA, GUSCARB, GUSCPE, GUTAXGEM, GUTIP, GUVEIP, GUVIP2 | **SM** SMILALD

#### Revised Protocols, PPPOs & Patient Handouts

**BR** BRAJDC, BRAJFCD, BRAJFCDT, BRAJTAM, BRAJTDC, BRAJTR, BRAVABR, BRAVDOC, BRAVDOC7, BRAVGEMD, UBRAVKAD, BRAVNAV, BRAVPTRAD, BRAVTAM, BRAVTCAP, BRAVTR, BRAVTRVIN, BRLAACD, BRLAACDT | **CN** CNCARV | **GI** GIA, GIAVPG, GICART, UGIGAVTRFT, GIIR, GIPAJGEM, GIPAVCAP, UGIPRRT, GIRAJCOX, GIRAJFFOX | **GO** GOCABR, GOCABRBEV, GOCXCAD, GOCXCAT, GOCXCATB, GOENDCAD, GOENDCAT, GOENDD, GOOVBEVG, GOOVBEVLD, GOOVBEVP, GOOVBEVV, GOOVCAD, GOOVCARB, GOOVCATM, GOOVCATR, GOOVDDCAT, GOOVFLDC, GOOVIPPC, GOOVLDOX, GOOVPLDC, GOOVTAM, GOSAD, GOSADG | **GU** GUAVD, GUAVPG, GUEDPM, GUMITO, GUSCARB | **HN** HNAVDOC, HNAVPD, HNAVCAP, HNAVGEM, HNAVPG, HNNLAPG, HNNLAPRT, HNOTAVD, HNSAVNP, HNSAVTAM | **LK** LKAMLCYT, LKCMLI, ULKMLP, ULKMDSL, ULKMFRUX, ULKPCVRUX, LKPEGIFN | **LU** LUSCPERT | **LY** LYCHOPR, LYCHOPRMTX, LYPALL, LYRICE, LYVIPDRT | **PU** PUCAT | **SA** KSLDO, KSVB, SAAI3, SAAVERIB, SAAVTW | **SM** USMAVIPNI, SMAVVC, SMDTIC

#### Resources and Contact Information

### Editor's Choice

#### New Programs

The BC Cancer Provincial Systemic Therapy Program has approved the following new treatment program effective 01 June 2021. The [Chemotherapy Protocols](#) section on the BC Cancer website has full details of all treatment programs.

#### Skin and Melanoma

**Intralesional Aldesleukin for In-Transit Melanoma (SMILALD)** — The BC Cancer Skin and Melanoma Tumour Group is implementing aldesleukin, a human interleukin-2 (IL-2) analogue, for the intralesional treatment of in-transit melanoma. In-transit metastatic melanoma lesions are cutaneous or subcutaneous deposits of melanoma that are often painful and disfiguring.<sup>1</sup> Although surgical excision is often used for in-transit melanoma metastases, for some patients the rapid development or large number of in-transit lesions precludes surgery. Two prospective, non-comparative phase II studies evaluated treatment with intralesional aldesleukin in patients with in-transit metastatic melanoma.<sup>2,3</sup> The complete response rates in both studies were high, both on a per-lesion basis (76%; 79%) and on an individual patient basis (51%; 65%). The treatment protocol provides full details for the preparation and administration of intralesional aldesleukin, which is administered in the surgical daycare setting. Pain and swelling at the injection site(s) and fever/flu-like symptoms are expected and typically managed with acetaminophen.

## Editor's Choice

### New Programs

#### References

1. Pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC). Final recommendation for aldesleukin (Proleukin®) for in-transit melanoma. 22 June 2015.
2. Boyd KU, Wehrli BM, Temple CLF. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. *J Surg Oncol* 2011;104:711–717. <https://doi.org/10.1002/jso.21968>
3. Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. *Cancer* 2010;116:4139-4146. <https://doi.org/10.1002/cncr.25156>

## Policy Updates

### BC Cancer Provincial Systemic Therapy Policy: Dose Banding

The BC Cancer Provincial Systemic Therapy Program has updated **Policy III-140: Management of Dose Banded Cancer Drug Treatments** effective 01 June 2021. All Systemic Therapy policies are available on the Shared Health Organizations Portal (SHOP) [BC Cancer page](#).

#### Why is the policy being updated?

To address changes due to Clinical Systems Transformation (CST) implementation.

#### Major changes include:

	Changes
<b>Title</b>	<ul style="list-style-type: none"><li>• The term 'chemotherapy' has been replaced by 'cancer drug treatment'</li></ul>
<b>Format</b>	<ul style="list-style-type: none"><li>• Updated to follow the new BC Cancer format</li><li>• Content has been separated into a policy document and a procedure document</li></ul>
<b>Policy</b>	<ul style="list-style-type: none"><li>• Added: due to technical capabilities of the Computerized Provider Order Entry (CPOE) system, dose-banding calculations may be applied only for certain medications in CST</li></ul>
<b>Procedure</b>	<ul style="list-style-type: none"><li>• Added procedures for sites using CST</li><li>• Created Appendix A: list of approved medications for which dose-banding will be applied at CST sites</li></ul>

### BC Cancer Provincial High-Alert Medications Policy

The **BC Cancer Provincial High-Alert Medications Policy** has been updated effective 01 June 2021. The policy is available on the Shared Health Organizations Portal (SHOP) [BC Cancer page](#).

#### Why are changes being made?

**V**ancouver Coastal, **P**rovidence Health and **P**rovincial Health Services Authority (VPP) are sharing a common Clinical Systems Transformation (CST) system. This system requires alignment of the VPP high-alert medication list. To reflect the changes made to the VPP high-alert medication list, BC Cancer has updated the BC Cancer Provincial High-Alert Medications Policy. Downstream processes such as the CST build and automated dispensing cabinet (ADC) flags will be revised accordingly.

#### How has the language in the overall policy been updated?

- Added computerized provider order entry (CPOE)
- Changed ‘chemotherapy’ to ‘cancer drug treatment’
- Added a link to [Nursing Practice Reference C-252 Chemotherapeutic Drugs, Administration of](#) to reference the independent double check (IDC) list and process

**All appendices have been moved to a separate document, with links embedded in the policy. Updates to the appendices include:**

Appendix	Changes
<b>A</b>	<p>Updated the oncology and non-oncology medications lists:</p> <ul style="list-style-type: none"> <li>• <b>Oncology drug list:</b> new drugs added</li> <li>• <b>Non-oncology drug list:</b> <ul style="list-style-type: none"> <li>○ Includes insulin:                             <ul style="list-style-type: none"> <li>▪ Formulations that are more concentrated than 100 units/mL</li> <li>▪ When given by IV continuous infusion</li> </ul> </li> <li>○ Magnesium 20% vial removed from list</li> <li>○ Removed concentration specification for methadone</li> <li>○ Routes specified: epidural; intrathecal; perineural; PCA</li> </ul> </li> </ul>
<b>B (new)</b>	<p>Outlines the evaluation criteria used for the inclusion or exclusion of BC Cancer Benefit Drugs on the Oncology High-Alert Medication List</p>
<b>C</b>	<p>Updated labelling, storage and wardstock requirements:</p> <ul style="list-style-type: none"> <li>• Removed IDC information from the policy; this information will be located in the NPR C-252</li> <li>• High-alert labelling on medication labels will be for CST sites only</li> <li>• Removed “hazardous drug” labelling information; the policy will focus on high-alert medication management only</li> <li>• Clarified that low molecular weight heparin multidose vials should not be dispensed to patients</li> <li>• Other changes that reflect the updated non-oncology drug list</li> </ul>
<b>D</b>	No changes
<b>E</b>	Updated the Automated Dispensing Cabinet Alerts table

## Cancer Drug Manual<sup>®</sup>

All BC Cancer Drug Manual<sup>®</sup> documents can be accessed from the [Cancer Drug Manual<sup>®</sup>](#) home page on the BC Cancer website.

### New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Sonidegib Interim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Corey Metcalf and Robert Tillmanns of the BC Cancer Skin and Melanoma Tumour Group. Sonidegib is an orally administered selective inhibitor of the Hedgehog signalling pathway, used in the treatment of basal cell carcinoma. The usual dose is 200 mg daily given continuously.

Highlights from these documents include:

- Sonidegib is only available through a controlled distribution program called the ODOMZO Pregnancy Prevention Program
- Musculoskeletal adverse events are common and include musculoskeletal pain, muscle spasms and myalgia
- Alopecia, dysgeusia and fatigue are frequently reported side effects

**Sonidegib** has been added to the **Auxiliary Label List** and has been evaluated for the **BC Cancer Hazardous Drug List**.

### Revised Documents

Highlights of key changes are listed below:

#### **Arsenic Trioxide Monograph** and **Chemotherapy Preparation and Stability Chart**

*Supply and Storage:* added vial formulation and updated manufacturer

*Chemotherapy Preparation and Stability Chart:* added vial formulation and updated stability for the ampoule formulation

## Benefit Drug List

### New Programs

The following new treatment program has been added to the BC Cancer [Benefit Drug List](#) effective 01 June 2021:

Protocol Title	Protocol Code	Benefit Status
Treatment of In-Transit Melanoma using Intralesional <b>Aldesleukin (IL-2)</b>	<b>SMILALD</b>	Class I

## Highlights of New & Revised Protocols, PPPOs and Patient Handouts

**BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

### NEW Protocols, PPPOs and Patient Handouts (*new documents checked* )

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UGIGAVTRFT	Third-Line Therapy of Advanced Gastroesophageal Carcinoma using Trifluridine-Tipiracil	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUAVD	Palliative Therapy for Advanced Adrenal Cortical Cancer using Doxorubicin	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUAXIT	Therapy for Metastatic Renal Cell Carcinoma using Axitinib	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUCABO	Therapy for Metastatic Renal Cell Carcinoma using Cabozantinib	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUEDPM	Treatment of Metastatic Adrenocortical Cancer with Etoposide, Doxorubicin, Cisplatin and Mitotane	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUEP	Therapy for Nonseminoma Germ Cell Cancer using Etoposide-Cisplatin	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUMVAC	Therapy for Transitional Cell Cancers of the Urothelium using Methotrexate, Vinblastine, Doxorubicin and Cisplatin	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
UGUNMPENZ	Therapy for Non-Metastatic Castration-Resistant Prostate Cancer using Enzalutamide	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
UGUPAPA	Treatment of Non-Metastatic Castration-Resistant Prostate Cancer using Apalutamide	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
UGUPENZ	Palliative Therapy for Metastatic Castration-Resistant Prostate Cancer using Enzalutamide	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUPLHRH	Therapy for Prostate Cancer using LHRH Agonist (Goserelin, Leuprolide or Buserelin)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUPLHRHA	Therapy for Advanced Prostate Cancer using LHRH Antagonist Degarelix	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUPMX	Palliative Therapy for Hormone-Refractory Prostate Cancer using Mitoxantrone and Prednisone	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUPNSAA	Non-Steroidal Treatment of Prostate Cancer	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>

## NEW Protocols, PPPOs and Patient Handouts (new documents checked )

Protocol Code	Protocol Title	Protocol	PPPO	Handout
GUSCARB	Adjuvant Therapy for Stage I High-Risk Seminoma using Carboplatin	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUSCPE	Palliative Therapy of Extensive-Stage Genitourinary Small Cell Tumours with a Platinum and Etoposide	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUTAXGEM	Palliative Therapy for Germ Cell Cancers using Paclitaxel and Gemcitabine	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUTIP	Therapy for Relapsed Testicular Germ Cell Cancer using Paclitaxel, Ifosfamide and Cisplatin (TIP)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUVEIP	Consolidation/Salvage Treatment for Germ Cell Cancer using Vinblastine, Cisplatin, Ifosfamide and Mesna	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
GUVIP2	Consolidation and Salvage Therapy for Nonseminoma using Etoposide, Cisplatin, Ifosfamide, Mesna	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
SMILALD	Treatment of In-Transit Melanoma using Intralesional Aldesleukin (IL-2)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/> Inpatient PPPO	<input checked="" type="checkbox"/>

## REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>BR   Breast</b>				
BRAJDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel and Cyclophosphamide	<i>Tests revised</i>	----	----
BRAJFCD	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel	<i>Tests revised</i>	----	----
BRAJFCDT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Fluorouracil, Epirubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>Tests revised</i>	----	----
BRAJTAM	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Tamoxifen	<i>Institution name updated; Tests revised</i>	<i>Tests revised</i>	----
BRAJTDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Trastuzumab, Docetaxel and Cyclophosphamide	<i>Tests revised</i>	----	----
BRAJTR	Adjuvant Therapy for Breast Cancer using Trastuzumab Following the Completion of Chemotherapy (Sequential)	<i>Tests revised</i>	<i>Tests revised</i>	----
BRAVABR	Palliative Therapy for Metastatic Breast Cancer using Paclitaxel NAB (ABRAXANE)	<i>Tests revised</i>	----	----

**REVISED Protocols, PPPOs and Patient Handouts** (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>BRAVDOC</b>	Palliative Therapy for Metastatic Breast Cancer using Docetaxel	<i>Tests revised</i>	----	----
<b>BRAVDOC7</b>	Palliative Therapy for Metastatic Breast Cancer using Weekly Docetaxel	<i>Tests revised</i>	----	----
<b>BRAVGEMD</b>	Palliative Therapy for Metastatic Breast Cancer using Gemcitabine and Docetaxel	<i>Tests revised</i>	----	----
<b>UBRAVKAD</b>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)	<i>Tests revised</i>	----	----
<b>BRAVNAV</b>	Palliative Therapy for Metastatic Breast Cancer using Vinorelbine	<i>Tests revised</i>	----	----
<b>BRAVPTRAD</b>	Palliative Therapy for Metastatic Breast Cancer using Pertuzumab, Trastuzumab (HERCEPTIN) and Docetaxel as First-Line Treatment for Advanced Breast Cancer	<i>Tests revised</i>	----	----
<b>BRAVTAM</b>	Palliative Therapy for Breast Cancer using Tamoxifen	<i>Institution name updated; Tests revised</i>	<i>Tests revised</i>	----
<b>BRAVTCAP</b>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Capecitabine	<i>Tests revised</i>	----	----
<b>BRAVTR</b>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab	<i>Tests revised</i>	----	----
<b>BRAVTRVIN</b>	Palliative Therapy for Metastatic Breast Cancer using Trastuzumab and Vinorelbine	<i>Tests revised</i>	<i>Tests revised</i>	----
<b>BRLAACD</b>	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Docetaxel	<i>Tests revised</i>	----	----
<b>BRLAACDT</b>	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>Tests revised</i>	----	----
<b>CN   Neuro-Oncology</b>				
<b>CNCARV</b>	Carboplatin and Etoposide in the Treatment of Recurrent Ependymoma and Oligodendroglioma	<i>Tests revised</i>	----	----
<b>GI   Gastrointestinal</b>				
<b>GIA</b>	Palliative Therapy for Hepatoma using Doxorubicin	<i>Institution name updated; Tests revised</i>	----	----
<b>GIAVPG</b>	First-Line Palliative Chemotherapy for Advanced Gallbladder Cancer and Cholangiocarcinoma using Gemcitabine and Cisplatin	<i>Tests revised</i>	----	----

**REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)**

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GICART</b>	Curative Combined Modality Therapy for Carcinoma of the Anal Canal using Mitomycin, Capecitabine and Radiation Therapy	<i>Tests revised</i>	----	----
<b>UGIGAVTRFT</b>	Third- <u>or Later</u> -Line Therapy of Advanced Gastroesophageal Carcinoma using Trifluridine-Tipiracil	<i>Protocol title and Eligibility updated</i>	----	----
<b>GIIR</b>	Palliative Chemotherapy of Metastatic Colorectal Cancer using Irinotecan	<i>CAP requirement for additional cycles removed</i>	<i>CAP statement deleted</i>	<i>Updated</i>
<b>GIPAJGEM</b>	Adjuvant Chemotherapy for Pancreatic Adenocarcinoma using Gemcitabine	<i>Institution name updated; Eligibility clarified</i>	----	----
<b>GIPAVCAP</b>	Second-Line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma using Capecitabine	<i>Tests revised</i>	----	----
<b>UGIPRRT</b>	Peptide Receptor Radionuclide Therapy (PRRT) using <sup>177</sup> Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor-Positive Midgut Neuroendocrine Tumours	<i>Octreotide PRN added for symptoms of carcinoid flare (Treatment, Precautions)</i>	<i>Octreotide PRN added for symptoms of carcinoid flare</i>	--
<b>GIRAJCOX</b>	Adjuvant <u>or Neoadjuvant</u> Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin and Capecitabine	<i>Protocol title and Eligibility updated</i>	----	----
<b>GIRAJFFOX</b>	Adjuvant <u>or Neoadjuvant</u> Combination Chemotherapy for Stage III Rectal Cancer using Oxaliplatin, Fluorouracil and Leucovorin	<i>Protocol title and Eligibility updated</i>	----	----
<b>GO   Gynecologic</b>				
<b>GOCABR</b>	Alternative Treatment of Gynecological Malignancies using Carboplatin and Paclitaxel NAB (ABRAXANE)	<i>Tests revised</i>	----	----
<b>GOCABRBEV</b>	Alternative Treatment of Gynecological Malignancies using Bevacizumab, Carboplatin and Paclitaxel NAB (ABRAXANE)	<i>Tests revised</i>	----	----
<b>GOCXCAD</b>	Primary Treatment of Advanced/Recurrent Non-Small Cell Cancer of the Cervix with Carboplatin and Docetaxel in Ambulatory Care Settings	<i>Tests revised</i>	<i>Institution name updated; AST removed</i>	----
<b>GOCXCAT</b>	Primary Treatment of Advanced/Recurrent Non-Small Cell Cancer of the Cervix with Carboplatin and Paclitaxel in Ambulatory Care Settings	<i>Tests revised</i>	<i>AST removed</i>	----
<b>GOCXCATB</b>	Primary Treatment of Metastatic or Recurrent Cancer of the Cervix with Bevacizumab, Carboplatin and Paclitaxel	<i>Tests revised</i>	----	----

**REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)**

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GOENDCAD</b>	Treatment of Primary Advanced or Recurrent Endometrial Cancer using Carboplatin and Docetaxel	<i>Tests revised</i>	<i>AST removed</i>	----
<b>GOENDCAT</b>	Treatment of Primary Advanced or Recurrent Endometrial Cancer using Carboplatin and Paclitaxel	<i>Tests revised</i>	<i>AST removed</i>	----
<b>GOENDD</b>	Doxorubicin for Use in Patients with Advanced Endometrial Cancer	<i>Institution name updated; Tests revised</i>	<i>Institution name updated; Tests revised</i>	----
<b>GOOVBEVG</b>	Treatment of Platinum-Resistant Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine	<i>Tests revised</i>	----	----
<b>GOOVBEVLD</b>	Treatment of Platinum-Resistant Epithelial Ovarian Cancer with Bevacizumab and Doxorubicin Pegylated Liposomal	<i>Tests revised</i>	----	----
<b>GOOVBEVP</b>	Treatment of Platinum-Resistant Epithelial Ovarian Cancer with Bevacizumab and Paclitaxel	<i>Tests revised</i>	----	----
<b>GOOVBEVV</b>	Treatment of Platinum-Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine	<i>Tests revised</i>	----	----
<b>GOOVCAD</b>	Primary Treatment with Visible or No Visible Residual Tumour (Moderate, High, or Extreme Risk) or Treatment at Relapse of Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer, using Carboplatin and Docetaxel	<i>Tests revised</i>	<i>AST removed</i>	----
<b>GOOVCARB</b>	First- or Second-Line Therapy for Invasive Epithelial Ovarian Cancer using Single-Agent Carboplatin	<i>Tests revised</i>	<i>AST removed</i>	----
<b>GOOVCATM</b>	Primary Treatment of No Visible Residual (Moderate - High Risk) Invasive Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer using Carboplatin and Paclitaxel	<i>Tests revised</i>	<i>AST removed</i>	----
<b>GOOVCATR</b>	Second-Line Treatment of Invasive Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Relapsing after Primary Treatment using Paclitaxel and Carboplatin	<i>Tests revised</i>	<i>AST removed</i>	----
<b>GOOVDDCAT</b>	Primary Treatment of Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma using Carboplatin and Weekly Paclitaxel	<i>Tests revised; Treatment duration clarified</i>	<i>AST removed</i>	----
<b>GOOVPLDC</b>	First-Line Treatment of Epithelial Ovarian Cancer using Doxorubicin Pegylated Liposomal and Carboplatin	<i>Tests revised</i>	----	----
<b>GOOVIPPC</b>	Primary Treatment of Stage III less than or equal to 1cm Visible Residual Invasive Epithelial Ovarian Cancer or Stage I Grade 3 or Stage II Grade 3 Papillary Serous Ovarian Cancer using Intravenous and Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin	<i>Tests revised</i>	<i>AST removed</i>	----

**REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)**

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>GOOVDOX</b>	Treatment of Epithelial Ovarian Cancer Relapsing after Primary Treatment using Doxorubicin Pegylated Liposomal	<i>Tests revised</i>	----	----
<b>GOOVPLDC</b>	Treatment of Epithelial Ovarian Cancer Relapsing after Primary Treatment using Doxorubicin Pegylated Liposomal and Carboplatin	<i>Tests revised</i>	----	----
<b>GOOVTAM</b>	Therapy for Advanced Ovarian Cancer using Tamoxifen	----	<i>Institution name updated; Tests revised</i>	----
<b>GOSAD</b>	Doxorubicin for Use in Patients with Advanced Uterine Sarcoma	<i>Institution name updated; Tests revised</i>	<i>Institution name updated; Tests revised</i>	----
<b>GOSADG</b>	Treatment of Uterine Sarcoma Cancer using Docetaxel and Gemcitabine	<i>Tests revised</i>	<i>AST removed</i>	----
<b>GU   Genitourinary</b>				
<b>GUAVD</b>	Palliative Therapy for Advanced Adrenal Cortical Cancer using Doxorubicin	<i>Institution name updated; Tests revised</i>	<i>Institution name and TALLman lettering updated; Tests revised</i>	----
<b>GUAVPG</b>	Palliative Therapy for Urothelial Carcinoma using Cisplatin and Gemcitabine	<i>Tests revised</i>	----	----
<b>GUEDPM</b>	Treatment of Metastatic Adrenocortical Cancer with Etoposide, Doxorubicin, Cisplatin and Mitotane	<i>Tests revised</i>	<i>Tests revised</i>	----
<b>GUMITO</b>	Treatment of Adrenal Cortical Cancer with Mitotane	<i>Institution name updated; Tests revised</i>	<i>Tests revised</i>	----
<b>GUSCARB</b>	Adjuvant Therapy for Stage I High-Risk Seminoma using Carboplatin	<i>Tests revised</i>	<i>AST removed</i>	----
<b>HN   Head and Neck</b>				
<b>HNAVDOC</b>	Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Docetaxel	<i>Tests revised</i>	<i>Institution name updated; Tests revised</i>	----
<b>HNAVPD</b>	Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Platinum and Docetaxel	<i>Tests revised</i>	----	----
<b>HNAVCAP</b>	Treatment of Recurrent or Metastatic Nasopharyngeal Cancer with Capecitabine	<i>Tests revised</i>	----	----
<b>HNAVGEM</b>	Treatment of Loco-Regionally Recurrent/Metastatic Nasopharyngeal Cancer Not Amenable for Local Curative Therapy with Gemcitabine	<i>Institution name updated; Tests revised</i>	----	----

**REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)**

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>HNNAVPG</b>	Treatment of Locoregionally Recurrent and/or Metastatic Nasopharyngeal Cancer with Platinum and Gemcitabine	<i>Tests revised</i>	----	----
<b>HNNLAPG</b>	Induction Treatment of Locally Advanced Nasopharyngeal Cancer with Cisplatin and Gemcitabine	<i>Institution name updated; Tests revised</i>	----	----
<b>HNNLAPRT</b>	Treatment of Locally Advanced Nasopharyngeal Cancer with Concurrent Cisplatin and Radiation	<i>Tests revised</i>	----	----
<b>HNOTAVD</b>	Palliative Therapy for Advanced Thyroid Cancers using Doxorubicin	<i>Institution name updated; Tests revised</i>	<i>Institution name updated; AST removed</i>	----
<b>HNSAVNP</b>	Palliative Treatment of Advanced Salivary Gland Cancers with Cisplatin and Vinorelbine	<i>Tests revised</i>	----	----
<b>HNSAVTAM</b>	Recurrent/Metastatic Salivary Gland Cancers of the Head and Neck with Tamoxifen	----	<i>Tests revised</i>	----
<b>LK   Leukemia</b>				
<b>LKAMLCYT</b>	Therapy of Acute Myeloid Leukemia using Low-Dose Cytarabine	<i>Tests revised</i>	<i>Tests revised</i>	----
<b>LKCMLI</b>	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Imatinib	<i>AST removed</i>	<i>AST removed</i>	----
<b>ULKCMLP</b>	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia using Ponatinib	<i>AST removed</i>	<i>AST removed</i>	----
<b>ULKMDSL</b>	Therapy of Myelodysplastic Syndrome using Lenalidomide	<i>Tests revised</i>	<i>Tests revised</i>	----
<b>ULKMFRUX</b>	Treatment of Symptomatic Myelofibrosis with Ruxolitinib	<i>AST removed</i>	<i>AST removed</i>	----
<b>ULKPCVRUX</b>	Treatment of Polycythemia Vera with Ruxolitinib	<i>Tests revised</i>	----	----
<b>LKPEGIFN</b>	Peginterferon Alfa-2a Therapy of Chronic Myeloid Neoplasms and Hypereosinophilic Syndrome	<i>AST removed</i>	<i>AST removed</i>	----
<b>LU   Lung</b>				
<b>LUSCPERT</b>	Treatment of Limited-Stage Small Cell Lung Cancer using Cisplatin and Etoposide with Radiation Therapy	<i>Tests revised</i>	----	----
<b>LY   Lymphoma</b>				
<b>LYCHOPR</b>	Treatment of Lymphoma with Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (CHOP-R)	<i>IV bag size clarified</i>	----	----

**REVISED Protocols, PPPOs and Patient Handouts (revisions in respective columns)**

Protocol Code	Protocol Title	Protocol	PPPO	Handout
<b>LYCHOPRMTX</b>	Central Nervous System Prophylaxis with High-Dose Methotrexate, CHOP and Rituximab in Diffuse Large B-Cell Lymphoma	<i>IV bag size clarified</i>	----	----
<b>LYPALL</b>	Lymphoma Palliative Chemotherapy	<i>Treatment options revised</i>	----	----
<b>LYRICE</b>	Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin's Lymphoma with Ifosfamide, Carboplatin, Etoposide and Rituximab	----	<i>Mesna PO administration clarified</i>	----
<b>LYVIPDRT</b>	Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-Cell Lymphoma, using Concurrent Radiation and Weekly Cisplatin Followed by Etoposide, Ifosfamide, Cisplatin and Dexamethasone	----	<i>Tests revised</i>	----
<b>PU   Primary Unknown</b>				
<b>PUCAT</b>	Primary Treatment of Cancer of Unknown Primary Origin using Carboplatin and Paclitaxel	<i>Tests revised</i>	----	----
<b>SA   Sarcoma</b>				
<b>KSLDO</b>	Therapy of Kaposi Sarcoma using Doxorubicin Pegylated Liposomal	<i>Contact Physician and Tests revised</i>	----	----
<b>KSVB</b>	Palliative Therapy for Kaposi's Sarcoma using Vinblastine Alternating with Vincristine	<i>Institution name updated; Contact Physician and Tests revised</i>	----	----
<b>SAAI3</b>	3-Day Doxorubicin-Ifosfamide-Mesna for Use in Patients with Advanced Soft Tissue Sarcoma	<i>Tests removed</i>	----	----
<b>SAAVERIB</b>	Palliative Therapy for Metastatic Sarcoma using Eribulin	<i>Tests clarified</i>	<i>Pretreatment metrics revised</i>	----
<b>SAAVTW</b>	Metastatic or Unresectable Angiosarcoma using Weekly Paclitaxel (3 Weeks out of 4 Weeks Schedule)	----	<i>Pretreatment metrics revised</i>	----
<b>SM   Skin and Melanoma</b>				
<b>USMAVIPNI</b>	Treatment of Unresectable or Metastatic Melanoma using Ipilimumab and Nivolumab	<i>Tests clarified; contact information updated</i>	<i>Tests clarified Induction and Maintenance PPPOs</i>	----
<b>SMAVVC</b>	Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Vemurafenib and Cobimetinib	<i>Tests clarified</i>	<i>Tests clarified</i>	----
<b>SMDTIC</b>	Palliative Therapy for Metastatic Malignant Melanoma using High-Dose Dacarbazine (DTIC)	<i>Tests revised</i>	<i>Tests revised</i>	----

## Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: <a href="http://www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update</a>		
Systemic Therapy Update Editor	604-877-6000 x 672649	<a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>
Oncology Drug Information	604-877-6275	<a href="mailto:druginfo@bccancer.bc.ca">druginfo@bccancer.bc.ca</a>
Cancer Drug Manual Editor	250-519-5500 x 693742	<a href="mailto:nbadry@bccancer.bc.ca">nbadry@bccancer.bc.ca</a>
Pharmacy Oncology Certification	250-712-3900 x 686820	<a href="mailto:rxchemocert@bccancer.bc.ca">rxchemocert@bccancer.bc.ca</a>
Nurse Educators	604-877-6000 x 672638	<a href="mailto:nursinged@bccancer.bc.ca">nursinged@bccancer.bc.ca</a>
CAP – Compassionate Access Program	604-877-6277	<a href="mailto:cap_bcca@bccancer.bc.ca">cap_bcca@bccancer.bc.ca</a> fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	<a href="mailto:oscar@bccancer.bc.ca">oscar@bccancer.bc.ca</a> fax 604-708-2051
Manufacturer Patient Assistance Programs: <a href="http://www.bccancer.bc.ca/mpap">http://www.bccancer.bc.ca/mpap</a>		
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 <a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Library Document Delivery	604-675-8002	<a href="mailto:requests@bccancer.bc.ca">requests@bccancer.bc.ca</a>
Pharmacy Professional Practice	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
Professional Practice, Nursing	604-877-6000 x 672623	<a href="mailto:BCCancerPPNAdmin@ehcnet.phsa.ca">BCCancerPPNAdmin@ehcnet.phsa.ca</a>
Provincial Systemic Therapy Program	604-877-6000 x 672247	<a href="mailto:mclin@bccancer.bc.ca">mclin@bccancer.bc.ca</a>
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: <a href="mailto:bulletin@bccancer.bc.ca">bulletin@bccancer.bc.ca</a>		

## Editorial Review Board

Anne Dar Santos, BScPharm, PharmD (Editor)  
 Fatima Ladha, BScPharm, PharmD (Assistant Editor)  
 Mario de Lemos, PharmD, MSc(Oncol)

Jeevan Dosanjh, RN, BScN  
 Alina Gerrie, MD, MPH, FRCPC  
 Alison Pow, BScPharm